SciELO - Scientific Electronic Library Online

 
vol.51 issue1CORRELATION BETWEEN PLATELET COUNT AND BOTH LIVER FIBROSIS AND SPLEEN DIAMETER IN PATIENTS WITH SCHISTOSOMIASIS MANSONIANALYSIS OF THE SURVIVAL OF CIRRHOTIC PATIENTS ENLISTED FOR LIVER TRANSPLANTATION IN THE PRE- AND POST-MELD ERA IN SOUTHERN BRAZIL author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Arquivos de Gastroenterologia

Print version ISSN 0004-2803

Abstract

KOTZE, Paulo Gustavo et al. ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN’S DISEASE: results of a Latin American single-center observational study. Arq. Gastroenterol. [online]. 2014, vol.51, n.1, pp.39-45. ISSN 0004-2803.  http://dx.doi.org/10.1590/S0004-28032014000100009.

Context

Adalimumab is a fully-human antibody that inhibits TNF alpha, with a significant efficacy for long-term maintenance of remission. Studies with this agent in Latin American Crohn’s disease patients are scarce.

Objectives

The objective of this study was to outline clinical remission rates after 12 months of adalimumab therapy for Crohn’s disease patients.

Methods

Retrospective, single-center, observational study of a Brazilian case series of Crohn’s disease patients under adalimumab therapy. Variables analyzed: demographic data, Montreal classification, concomitant medication, remission rates after 1, 4, 6 and 12 months. Remission was defined as Harvey-Bradshaw Index ≤4, and non-responder-imputation and last-observation-carried-forward analysis were used. The influence of infliximab on remission rates was analyzed by Fischer and Chi-square tests (P<0.05).

Results

Fifty patients, with median age of 35 years at therapy initiation, were included. Remission rates after 12 months of therapy were 54% under non-responder-imputation and 88% under last-observation-carried-forward analysis. After 12 months, remission on patients with previous infliximab occurred in 69.23% as compared to 94.59% in infliximab-naïve patients (P = 0.033).

Conclusions

Adalimumab was effective in maintaining clinical remission after 12 months of therapy, with an adequate safety profile, and was also more effective in infliximab naïve patients.

Keywords : Tumor necrosis factor-alpha; Adrenergic alpha-antagonists, administration and dosage; Crohn disease, prevention and control.

        · abstract in Portuguese     · text in English     · English ( pdf )